We discover and develop more effective therapeutics, enable healthier choices, innovate sustainable processes and products, and reduce waste – all to create a brighter future. This unified vision is what drives Codexis to continually set high standards and raise expectations of what is possible and its impact on the world and communities around us.
Enabling sustainable processes and products is our priority towards reducing waste, pollution, and consumption. Enzymes, nature’s biocatalysts for millions of years, are significantly more safe for the environment than are chemicals. We engineer high-performance enzymes to enable industrial bioprocesses that address productivity needs without sacrificing the health of our planet.
We are committed to effective biological therapeutics and accurate health monitoring tools. Annually, Codexis participates in global Rare Disease Day and also hosts its own event, welcoming guests and patient support groups with onsite activities. Whether it is for novel pharmaceuticals, protein therapies, gene therapies, biosensors, or upstream research and development, our work – evolved enzymes – makes an impact on someone’s life daily. This is why we at Codexis continue to work harder and smarter; we believe every breath and every heartbeat matters.
As a socially responsible company, Codexis strives to play a positive role by fostering a culture that promotes employee volunteering to support the communities where we operate. We participate in multiple initiatives throughout the year supporting local charitable organizations, Family Giving Tree, and Second Harvest Food Bank. To promote youth education, Codexis sponsors Future Protein Engineers, an online program encouraging innovation and creativity while having fun learning about science.
Codexis spun-out from Maxygen
Codexis IPO on Nasdaq
Merck – FDA approval for sitagliptin API process using CDX-017
GlaxoSmithKline – CodeEvolver® platform license
Merck – CodeEvolver® platform license
First commercial enzyme sold to food industry with Tate & Lyle
First partnering deal in biotherapeutics with Nestlé Health Science
Commercialized enzymes for Tate & Lyle Tasteva M® Stevia sweetener
First successful clinical trial completed: CDX-6114 for PKU
Novartis CodeEvolver® platform license
Evo T4 DNA Ligase for next gen sequencing licensed to Roche
Extended biotherapeutics partnering deal with Nestlé Health Science
Takeda – gene therapy collaboration and license agreement
Launched three life science enzymes with Alphazyme
Molecular Assemblies – partnered on enzymatic DNA synthesis
Improved Enzymes to Further Enhance Tate & Lyle’s Stevia and Allulose Production
Join us on our journey.